Cantargia AB (OSTO:CANTA)

kr 1.67 -0.045 (-2.62%) Market Cap: 415.18 Mil Enterprise Value: 355.37 Mil PE Ratio: 0 PB Ratio: 6.28 GF Score: 20/100

Q3 2024 Cantargia AB Earnings Call Transcript
Nov 15, 2024

kr1.9 (-0.99%)

Earnings
Q2 2024 Cantargia AB Earnings Call Transcript
Aug 28, 2024

kr3.99 (+1.17%)

Earnings
Q3 2023 Cantargia AB Earnings Call Transcript
Nov 10, 2023

kr3.61 (-10.20%)

Earnings
Q2 2023 Cantargia AB Earnings Call Transcript
Aug 22, 2023

kr4.25 (+1.58%)

Earnings
Q1 2023 Cantargia AB Earnings Call Transcript
May 23, 2023

kr4.89 (+5.89%)

Earnings
Q4 2022 Cantargia AB Earnings Call Transcript
Feb 23, 2023

kr6.03 (-16.49%)

Earnings
Q3 2022 Cantargia AB Earnings Call Transcript
Nov 10, 2022

kr3.59 (-7.33%)

Earnings
Q2 2022 Cantargia AB Earnings Call Transcript
Aug 30, 2022

kr4.14 (+0.15%)

Earnings
Cantargia AB Briefing on Update Recently Announced Rights Issue Transcript
Jul 07, 2022
Q1 2022 Cantargia AB Earnings Call Transcript
May 23, 2022

kr11.98 (+2.20%)

Earnings
Q4 2021 Cantargia AB Earnings Call Transcript
Feb 24, 2022

kr14.11 (+2.42%)

Earnings

Q2 2024 Cantargia AB Earnings Call Transcript

Aug 28, 2024 / 01:00PM GMT

Release Date Price: kr3.99 (+1.17%)

Transcript

Goeran Forsberg

Cantargia AB - Chief Executive Officer

Thank you. It's a pleasure to present Cantargia half year report of what I think has been a very exciting period in the company. So to take you into the highlights, we've had a very good news flow regarding both our clinical programs.

But what I really like to point out here is that Cantargia has taken a major step forward that we now have 2 clinical programs of significance. So the CAN10 program past a number of important milestones during the period. So we are almost completed with the initial sub part of the Phase I trial and that means single dosing.

And we've had the independent safety review on unblinded data that has not picked up any safety concerns. So the safety is obviously very good on CAN10. But we also start to generate the biomarker data, which shows that we have a very potent drug. So for instance, we've documented receptor binding on to the target IL1RAP on immune cells at a relatively early and predictive dose level.

And we also generated strong biomarker data. So we'll present more about that in -- when

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.